For US residents only.



A 20-year commitment to research in CML

For 20 years, Novartis has been committed to research in chronic myeloid leukemia (CML).

While today’s medications help many people with CML, some patients do not do as well.

If this sounds a lot like what you’re going through, be sure to check out the resources on this website and, sign up to receive updates about CML.

Track your CML journey

You may find it helpful to track your treatment for CML, whether it’s recording the results of blood tests, notes from speaking with your doctor, or simply how you’re feeling. Some people prefer to use a journal to capture their thoughts. Others use one of the many tracker apps available. One of these apps is called Belong—Beating Cancer Together.

As a social network for managing and navigating cancer treatment, the Belong app connects CML patients and caregivers. It’s anonymous and free.

You can download the Belong app from Google Play or the App Store. To learn more, visit

Resources for patients with CML

As a rare cancer, CML does not receive the same attention as some of the more common forms of cancer. You may find it helpful to reach out to the organizations listed below for information, support, or to connect with others who are living with CML.


Leukemia & Lymphoma Society®



The National CML Society



The Max Foundation




1-800-813-HOPE (1-800-813-4673)


Leukemia Research Foundation



American Cancer Society®

1-800-ACS-2345 (1-800-227-2345)


National Cancer Institute’s Cancer Information Service

1-800-4CANCER (1-800-422-6237)

Those with TTY equipment may call 1-800-322-8615


National Patient Advocate Foundation



The organizations and websites listed on this page are maintained by third parties over whom Novartis Pharmaceuticals Corporation has no control. As such, Novartis Pharmaceuticals Corporation makes no representation as to the accuracy or any other aspect of the information supplied by these organizations or contained in these websites.

Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.

11/21 170520